Major Depressive Disorders Have an Enormous Economic Impact
Scientific American, 2021
Writing in Scientific American, Managing Principal Paul E. Greenberg reported on the latest findings from a 30-year study tracking the true cost of major depressive disorders (MDD) in the US. The research was conducted by a team including Mr. Greenberg, Senior Advisor Tamar Sisitsky, Vice President Andree-Anne Fournier, Associate Mark Simes, and Senior Analyst Richard Berman from Analysis Group; and Harvard Medical School Professor Ronald C. Kessler.
In his article, Mr. Greenberg noted that the incremental economic burden of adults with MDD in the US rose by 38% between 2010 and 2018, reaching $326 billion. Importantly, the share of the overall burden attributable to costs for direct medical treatment of MDD and comorbidities declined over that period, while the share of workplace-related costs increased. The 2018 data also revealed that the illness was more prevalent among younger people than in 2010, and that treatment rates for MDD sufferers overall showed no improvement over that time, suggesting that a substantial unmet treatment need still exists.
The full findings from the 2018 update were published in PharmacoEconomics.
Read the Scientific American article
Read the paper in PharmacoEconomics